Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Manufacturer's Recall of Rapid Cartridge Assay Kits on the Basis of
False-Positive Cryptosporidium Antigen Tests --- Colorado, 2004
The Colorado Department of Public Health and Environment (CDPHE) has determined that a fourfold increase in
the number of reported cryptosporidiosis cases in Colorado during January--February 2004 might be attributed primarily to false-positive test results. Since January 1, 2004, a total of 13 in-state cases and one out-of-state case were reported to CDPHE. During the previous 7 years, an average of three cases were reported during January--February. In eight of 14 patients, rapid testing was performed by using the ImmunoCard
STAT!®Cryptosporidium/Giardia Rapid Assay (Meridian Bioscience,
Inc., Cincinnati, Ohio). This assay is a solid-phase qualitative immunochromatographic assay designated to detect and distinguish between Giardia intestinalis
(lamblia) and Cryptosporidium parvum in aqueous extracts of human fecal specimens. Seven
of these samples were tested by using lot no. 081093 (expires August 11, 2004). Of the seven samples that tested positive
initially for Cryptosporidium with this lot number, four were retested by using other, more specific tests. One patient sample
was positive by direct microscopy, one was negative by direct microscopy, and two were negative by direct
fluorescent-antibody testing, suggesting that results for three of the four samples were false positive. The results of testing for
Giardia intestinalis (lamblia) with these kits are unclear. Several other states have noted increases in the number of reported cryptosporidiosis cases that also might be associated with use of these rapid assays.
Meridian Bioscience, Inc., has voluntarily recalled two lots (lot no. 081077 [expires July 11, 2004] and lot no.
081093) from laboratories. CDC recommends reconfirmation of positive test results obtained with ImmunoCard
STAT!® rapid assays from these lots.
Reported by: A Cronquist, MPH, Colorado Dept of Public Health and Environment. MJ Beach, PhD, SP Johnston, MS, A da Silva, PhD, Div of Parasitic Diseases, National Center for Infectious Diseases, CDC.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
